Impact of Omalizumab on Corticosteroid Use, Emergency Room Visits and Hospitalizations

Novartis

Status: Withdrawn

Conditions: Asthma

Study type: Observational

Funder types: Industry

Identifiers

NCT01460862

HEORUS0091

Details and patient eligibility

About

A retrospective database analysis to evaluate the impact of omalizumab on the use of corticosteroid, emergency-department visits and hospitalizations among patients with uncontrolled asthma and using high-dose Inhaled Corticosteroids (ICS) prior to initiating omalizumab.

Sex: All

Ages: 12+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• ≥12 years of age with a documented Cystic fibrosis (CF) diagnosis,
• on Long acting Beta antagonist- Inhaled Corticosteroid (LABA-ICS) at baseline,
• uncontrolled asthma at baseline.

Exclusion criteria

Other protocol-defined inclusion/exclusion criteria may apply.

Trial design

0 participants in 1 patient group

Omalizumab Cohort